Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
MeiraGTx logo — Engineering Hope

MeiraGTx

Engineering Hope

Founded 2015 United Kingdom United Kingdom 419 employees IPO Total: $356.00M Biotechnology, Health Care +1

General Information

Company Name MeiraGTx
Founded Year 2015
Location United Kingdom United Kingdom
Employees 419
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage IPO
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with MeiraGTx. To contact MeiraGTx, visit meiragtx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does MeiraGTx compare?

A PDF of MeiraGTx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting MeiraGTx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About MeiraGTx

MeiraGTx, founded in 2015, is a prominent player in the biotechnology sector, headquartered in the United Kingdom. Known for "Engineering Hope," this Nasdaq-listed company (MGTX) is establishing itself in the genetic medicine landscape with a vertically integrated structure. Their infrastructure includes two GMP viral vector production facilities and an in-house Quality Control hub, underscoring their end-to-end capabilities from development to commercialization.

MeiraGTx specializes in developing viral vector design and precision gene regulation technologies, with applications in metabolic peptide delivery and cell therapy for oncology and autoimmune conditions. Expanding beyond initial focuses like the eye, central nervous system, and salivary gland, they aim to tackle broader disease areas with high unmet needs.

The company's most recent financial milestone is a $30.00M Post-IPO Equity investment from Sanofi as of October 30, 2023, highlighting confidence from established pharmaceutical players.

Business keywords: genetic medicine, gene therapy, viral vector production, riboswitch gene regulation, metabolic peptides, GLP-1, GIP, oncology cell therapy, autoimmune disease treatment, GMP manufacturing, plasmid production, rare diseases, neurodegenerative diseases, inherited retinopathies, clinical-stage biotechnology

Services & Products

Development of genetic therapies
Precision control of gene expression
In-vivo delivery platform
End-to-end GMP manufacturing

Target Customers

Patients with rare diseases Patients with prevalent genetic conditions Medical institutions Research organizations

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $100.00M -
01 Apr 2026
Post-IPO Equity $30.00M 1
Sanofi
01 Oct 2023
Private Placement VC $60.00M 4
Adage Capital Management Perceptive Advisors 683 CAPITAL
Adage Capital Management, Perceptive Advisors +2
01 May 2023
Post-IPO Debt $75.00M 1
Perceptive Advisors
Perceptive Advisors
01 Aug 2022
Series B $86.00M -
01 May 2018
Grant Undisclosed 2
Target ALS
Target ALS, ALS Finding a Cure
01 Feb 2017
Early VC $5.00M 1
Essex Bio
01 Mar 2016
Spinout Undisclosed 1
University College London
01 Jan 2015

MeiraGTx Alternatives & Competitors

View All Alternatives
MeiraGTx vs
bluebird bio
bluebird bio United States

Pursuing curative gene therapies to give patients and their families more bluebird days.

IPO
548 employees
Biotechnology, Health Care
MeiraGTx vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
34 employees
Biotechnology, Health Care
MeiraGTx vs
Code Biotherapeutics
Code Biotherapeutics United States

Pioneering targeted delivery of precision genetic medicines

Series A
23 employees
Biotechnology, Health Care
View all alternatives

FAQ About MeiraGTx

Engineering Hope
MeiraGTx was founded in 2015.
MeiraGTx is headquartered in United Kingdom.
MeiraGTx operates in Biotechnology, Health Care and Health and Wellness. Its work centres on genetic medicine, gene therapy, viral vector production and riboswitch gene regulation. Its customers include Patients with rare diseases, Patients with prevalent genetic conditions and Medical institutions.
MeiraGTx has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Service Fee.
MeiraGTx has approximately 419 employees.
MeiraGTx has completed 8 funding rounds, raising a total of $356.00M. The latest funding stage is IPO.
MeiraGTx offers: Development of genetic therapies, Precision control of gene expression, In-vivo delivery platform, End-to-end GMP manufacturing.
Top alternatives and competitors to MeiraGTx include bluebird bio, Affinia Therapeutics, Code Biotherapeutics, Orchard Therapeutics - U.S., Solid Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MeiraGTx and bluebird bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for MeiraGTx, https://bouncewatch.com/company/meiragtx, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes